GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
Business & Industry
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
- GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
- Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children 5 through 11 years of age in European Union
- Vividion Therapeutics names Jenna Goldberg as Chief Medical Officer
Research & Development
- AI tailors artificial DNA for future drug development
- Remdesivir reduces COVID-19 mortality in a real-world setting
- Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
- Cryptic drug-binding sites discovered in the dance
- Unusual type of antibody shows ultrapotent activity against Zika
- Machine learning can help predict patient response to cancer immunotherapy
- New drug shows promise for fighting both COVID-19 and cancer
Conferences & Events
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
Regulatory Affairs
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals